Altimmune (ALT) vs Crescent Biopharma (CBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Altimmune (ALT) over the past year, gaining 19.5% versus a loss of 32.3%. Over five years, ALT leads with a -77.9% price change compared with -93.2% for CBIO. Crescent Biopharma is the larger company by market cap ($523.8 million vs $505.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | CBIO |
|---|---|---|
| Share price | $2.60 | $14.10 |
| Market cap | $505.75M | $523.77M |
| 1-day change | -2.26% | +4.52% |
| YTD return | -26.32% | +13.74% |
| 1-year return | -32.32% | +19.49% |
| 5-year return | -77.85% | -93.19% |
| EPS (TTM) | $-0.76 | $-7.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $27.41 |
| 52-week low | $2.55 | $8.72 |
| Distance from 52-week high | -59.63% | -48.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +558.08% | +123.40% |
| Average volume | 4.18M | 397.58K |
| Shares outstanding | 194.52M | 37.14M |
| Employees | 57 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed ALT by 51.8 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
ALT vs CBIO FAQ
Which is bigger, Altimmune or Crescent Biopharma?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $523.77M compared with $505.75M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or CBIO?
CBIO returned +19.49% over the past 12 months, compared with -32.32% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Crescent Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.